Targeting CD47-SIRPα axis for Hodgkin and non-Hodgkin lymphoma immunotherapy
作者机构：School of Life Sciences and MedicineShandong University of TechnologyZiboShandong 255000China Tongji University Cancer CenterShanghai Tenth People's HospitalSchool of MedicineTongji UniversityShanghai 200092China
出 版 物：《Genes & Diseases》 (基因与疾病（英文）)
年 卷 期：2024年第11卷第1期
页 面：205-217页
核心收录：
学科分类：0710[理学-生物学] 1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金：supported by the National Key Research and Development Program of China(No.2020YFA0803201) the National Natural Science Foundation of China(No.31830053,31920103007,22207084) the Fundamental ResearchFunds fortheCornellUniversity(No.22120220463)
主 题：Cancer treatment CD47-SIRPαaxis Hodgkin lymphoma Immunotherapy Non-Hodgkin lymphoma
摘 要：The interaction between cluster of differentiation 47(CD47)and signal regulatory proteinα(SiRPa)protects healthy cells from macrophage attack,which is crucial for maintain-ing immune *** of CD47 occurs widely across various tumor cell types and transmits thedon t eat mesignal to macrophages to avoid phagocytosis through binding to *** of the CD47-SIRPa axis is therefore a promising approach for cancer *** is the most common hematological malignancy and is an area of unmet clin-ical *** review mainly described the current strategies targeting the CD47-SIRPa axis,including antibodies,SiRPaFc fusion proteins,small molecule inhibitors,and peptides both in preclinical studies and clinical trials with Hodgkin lymphoma and non-Hodgkin lymphoma.
维普期刊数据库